In conclusion, the current study presents a typical trend for the association between the presence of DAPK1 promoter methylation and a variety of BCR-ABL mutations, regardless of any characteristics of the CML patients, such tumor stage, gender or age. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.